Sirolimus for solid organ transplantation in children
Authors:
- 17 May 2005
- journal article
- Published by Wiley in Pediatric Transplantation
- Vol. 9 (3) , 269-276
Abstract
Abstract: Sirolimus represents a major advancement in the field of solid organ transplantation and is being used as a rescue agent for acute and chronic rejection as well as for primary immunosuppression with good graft outcome. Although initial studies with sirolimus were in adults, now significant data have accumulated on the role of sirolimus in pediatric solid organ transplantation. This article reviews the current status of sirolimus in pediatric transplantation.Keywords
This publication has 55 references indexed in Scilit:
- Studies of Pediatric Liver Transplantation 2002: Patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and CanadaPediatric Transplantation, 2004
- Short sirolimus half‐life in pediatric renal transplant recipients on a calcineurin inhibitor‐free protocolPediatric Transplantation, 2004
- Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune®, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis1Pediatric Transplantation, 2004
- Pharmacokinetics of Sirolimus and Tacrolimus in Pediatric Transplant PatientsAmerican Journal of Transplantation, 2004
- Islet Transplantation as a Treatment for Diabetes — A Work in ProgressNew England Journal of Medicine, 2004
- Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantationTransplantation, 2004
- Pharmacokinetic Interactions between Sirolimus and Microemulsion Cyclosporine When Orally Administered Jointly and 4 Hours Apart in Healthy VolunteersThe Journal of Clinical Pharmacology, 2003
- Orthotopic liver transplantation using low-dose tacrolimus and sirolimusLiver Transplantation, 2001
- Sirolimus in pediatric gastrointestinal transplantation: The use of sirolimus for pediatric transplant patients with tacrolimus‐related cardiomyopathyPediatric Transplantation, 2000
- ABROGATION BY RAPAMYCIN OF ACCELERATED REJECTION IN SENSITIZED RATS BY INHIBITION OF ALLOANTIBODY RESPONSES AND SELECTIVE SUPPRESSION OF INTRAGRAFT MONONUCLEAR AND ENDOTHELIAL CELL ACTIVATION, CYTOKINE PRODUCTION, AND CELL ADHESION1,2Transplantation, 1994